Molecular docking and in vitro anticancer evaluation of potential compounds derived from Indonesian sponge Agelas nakamurai
Indian Journal of Pharmacology · 2025
DOI: 10.4103/ijp.ijp_701_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Pharmacology, 2025. Verfasst von Fitri Budiyanto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Antineoplastic Agents, Porifera. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
OBJECTIVE: This study evaluated the anticancer activity ( in silico and in vitro ) of compounds derived from the Agelas nakamurai collected from Indonesian waters against the triple-negative breast cancer cancer cell line MDA-MB-231. BACKGROUND: The marine sponge genus Agelas is known to biosynthesize a variety of secondary metabolites with anticancer properties. MATERIALS AND METHODS: The compounds were separated using open column and preparative high-performance liquid chromatography. The liquid chromatography-mass spectrometry/mass spectrometry and nuclear magnetic resonance data were used to characterize compounds. Antiproliferation test of isolated compounds was conducted against the MDA-MB-231 cell line. Meanwhile p53 MDM2 protein [PDB]: 4OQ3, and Estimated Glomerular Filtration Rate (EGFR) protein (PDB: 1T46) were utilized for molecular docking and dynamic (MD) analysis. RESULTS: LC-MS data of fraction F7 indicated the presence of agelasine D, ageloxime D, agelanin B, and midpacamide. Further purification of fraction F7 led to the agelasin D and ageloxime D. Both compounds inhibited the MDA-MB-231 cell line with IC 50 values of 7.09 and 171.07 µM, respectively. The docking results showed that the binding affinity of agelasine D and ageloxime D to 4OQ3 and 1T46 were close, with scores ranging from −7.3 to −9.0 kcal/mol. MD simulation within 100 ns indicated agelasin D and ageloxime-D make stable binding to the targeted proteins with root-mean-square deviation
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia.
- Department of Pharmaceutical Biology, Faculty of Pharmacy, Padjajaran University, Bandung, Indonesia.
Zitieren
APA
Budiyanto, F., Bustanussalam, B., Hapsari, Y., Hadisaputri, Y. E., Wibowo, J. T., Untari, F., & Murniasih, T. (2025). Molecular docking and in vitro anticancer evaluation of potential compounds derived from Indonesian sponge Agelas nakamurai. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_701_24
Vancouver
Budiyanto F, Bustanussalam B, Hapsari Y, Hadisaputri YE, Wibowo JT, Untari F, et al. Molecular docking and in vitro anticancer evaluation of potential compounds derived from Indonesian sponge Agelas nakamurai. Indian Journal of Pharmacology. 2025. doi:10.4103/ijp.ijp_701_24
BibTeX
@article{Budiyanto2025,
author = {Budiyanto, Fitri and Bustanussalam, Bustanussalam and Hapsari, Yatri and Hadisaputri, Yuni Elsa and Wibowo, Joko Tri and Untari, Febriana and Murniasih, Tutik},
title = {Molecular docking and in vitro anticancer evaluation of potential compounds derived from Indonesian sponge Agelas nakamurai},
journal = {Indian Journal of Pharmacology},
year = {2025},
doi = {10.4103/ijp.ijp_701_24}
}
EUVIMED